MS4A1
B-lymphocyte antigen CD20
As of the edition of 20 October 2026, MS4A1 (B-lymphocyte antigen CD20, UniProt P11836) has 38 drugs tested at it and 33 companies on the list, 9 on route A and 9 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11836
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 10
- Disease areas
- Immune system; Blood and lymph; Cancer; Skin and connective tissue; Nervous system; Heart and blood vessels; Infections; Bones, joints and muscles
- Registered trials of its drugs
- 2,657
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 13 |
| Active | 11 |
| Went quiet | 4 |
| Stopped | 9 |
| Status not established | 1 |
| Total | 38 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Rituximab | Marketed | Phase 4 | Ends 2028 |
| Obinutuzumab | Marketed | Phase 4 | Ended 2025 |
| Ofatumumab | Marketed | Phase 4 | Ended 2023 |
| Glofitamab | Marketed | Phase 4 | Ends 2035 |
| Ocrelizumab | Marketed | Phase 4 | Ends 2029 |
| Epcoritamab | Marketed | Phase 3 | Ends 2035 |
| Mosunetuzumab | Marketed | Phase 3 | Ends 2034 |
| Ublituximab | Marketed | Phase 4 | Ends 2034 |
| Yttrium y 90 ibritumomab tiuxetan | Marketed | Phase 3 | Ended 2014 |
| Tositumomab | Marketed | Phase 3 | Ended 2015 |
| Ibritumomab tiuxetan | Marketed | Phase 3 | Ended 2014 |
| Odronextamab | Marketed | Phase 3 | none listed |
12 of 38 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 9 |
| Route B | 9 |
| Engaged | 13 |
| Undetermined | 2 |
| Total on the list | 33 |
The other 30 companies at MS4A1
In the product33 companies in all; 30 are not named here, and no score is.
See the 33 companies at MS4A1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.